Pipeline Report November 2020

Total Page:16

File Type:pdf, Size:1020Kb

Pipeline Report November 2020 Pipeline Report November 2020 Pipeline Report November 2020 © 2020 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs: Recent Specialty Drug Approvals1 1 > On COVID-19, the FDA granted full approval to Veklury (remdesivir) for the treatment of COVID-19. Veklury is approved for use in hospitalized adults and pediatric patients (≥ 12 years of age and weighing ≥ 40 Recent Non-Specialty Drug Approvals 6 kg), and represents the very first therapy to garner full FDA approval for COVID-19. Other therapies will follow, gaining market access through EUA (LLY’s Bamlanivimab and Olumiant, and <likely> Regeneron’s Upcoming Specialty Products 7 REGN-COV2). With the US crossing the 11 million total coronavirus infection mark, demand for these agents will be high while supply of the antibody treatment will be especially tight. The vaccine race accelerates as there are now two m-RNA based candidates both showing greater than 94% Upcoming Non-Specialty Products 15 efficacy in study populations. Both vaccines require 2 doses. Neither has FDA approval, and EUA reviews are pending. Supplies will be limited for months to come. Pfizer has stated it could produce 50 million doses by the end of 2020, and Moderna has promised up to 20 million doses in the same time frame. During 2021 Pfizer Biosimilars 18 forecasts 1.3 billion doses while Moderna states between 500 million and 1 billion. > Other therapies approved promise to expand and enhance patient options over currently available therapies, including Sogroya for growth hormone deficiency, Kesimpta for multiple sclerosis, and Enspryng for neuromyelitis Generic Specialty Agents 19 optica spectrum disorder. > Looking forward, we are awaiting FDA action on several key pipeline agents that each represent first-time therapies for rare or ultra-rare conditions, including Hutchinson-Gilford Progeria syndrome, Niemann-Pick type Generic Non-Specialty Agents 21 C disease, genetically mediated obesity, and molybdenum cofactor deficiency type A. > Additionally, aducanumab is another potential new treatment for a much more common condition – mild or prodromal Alzheimer’s disease. Despite a recent FDA Advisory Committee vote against FDA approval, the FDA is not required to take the advice of the Committee, and as such there remains the possibility of FDA approval in light of the intense unmet need identified in the treatment armamentarium for Alzheimer’s disease. To prepare this report, our team accesses a wide range of clinical resources. This information is then analyzed, resulting in updates across multiple disease states including recent and anticipated drug approvals, key changes in the biosimilar agent landscape, and notes on recent and anticipated generic product launches. Our pipeline report is just one of many ways we’re committed to providing helpful tools and resources to our clients and partners. We look forward to sharing more updates with you in the months ahead. Ross Hoffman, MD To provide comments, feedback or requests for report enhancements, please email us at [email protected]. Pipeline Report Recent Specialty Drug Approvals November 2020 FDA AcariaHealth (AH) Drug Name Manufacturer(s) Indication(s) Approval Comments Cost (WAC) Access Status Date ENDOCRINOLOGY • Approved for the treatment of adults. Sogroya • Once weekly dosing. somapacitan-beco • Growth hormone • NovoNordisk 8/28/20 Pending launch • Estimated prevalence of adult GHD: 2-3 per Pending launch subcutaneous deficiency (GHD) 10,000 people. injection • Projected impact: cost replacement of existing therapies. INFECTIOUS DISEASES Inzameb • For the treatment of infection caused by Zaire atoltivimab, ebolavirus in adult and pediatric patients, • Zaire ebolavirus maftivimab, • Regeneron 10/14/20 Pending launch including neonates born to a mother who is RT- Pending launch infection odesivimab-ebgn PCR positive for Zaire ebolavirus infection. intravenous infusion • Projected impact: cost increase. $3,120/5-day • Approved for adults and pediatric patients (≥ course of Veklury • Coronavirus 12 years of age and weighing ≥ 40 kg) requiring therapy remdesivir • Gilead disease 2019 10/22/20 Limited access hospitalization due to COVID-19. intravenous infusion (COVID-19) $5,720/10- • Projected impact: cost increase. day course of therapy © 2020 Envolve. All rights reserved. Continued Page 1 Pipeline Report Recent Specialty Drug Approvals November 2020 FDA AcariaHealth (AH) Drug Name Manufacturer(s) Indication(s) Approval Comments Cost (WAC) Access Status Date • An Emergency Use Authorization (EUA) was granted for the emergency treatment of mild to moderate disease in adults and pediatric patients with positive results of direct SARS- CoV-2 viral testing who are 12 years of age and older weighing ≥ 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. The U.S. Note: an EUA is not the same as full FDA government will LY-CoV555 approval. cover the cost of bamlanivimab • Eli Lilly • COVID-19 11/9/20 Limited access the first 300,000 intravenous infusion • Eli Lilly will ship the first 300,000 doses of bamlanivimab bamlanivimab to AmerisourceBergen, which will doses. distribute it as directed by the U.S. government's allocation program. Weekly allocation decisions will be proportionally based on confirmed COVID-19 cases in each state and territory over the previous seven days. • Projected impact: cost increase after U.S. government cost coverage ends • An EUA was granted for emergency use of Olumiant, in combination with remdesivir (Veklury), for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized Age 2-8 years: adults and pediatric patients 2 years of age or $1,057/14- older requiring supplemental oxygen, invasive day course of Olumiant mechanical ventilation, or extracorporeal therapy baricitinib • Eli Lilly • COVID-19 11/19/20 AH has access membrane oxygenation. oral tablets Note: an EUA is not the same as full FDA Age 9 years and approval. older: $2,114/14- • Under the EUA, inpatient pharmacies in the U.S. day course of may order Olumiant through Lilly authorized therapy specialty distributors. A current list of Lilly's authorized distributors of record for the EUA is available at lillytrade.com. © 2020 Envolve. All rights reserved. Continued Page 2 Pipeline Report Recent Specialty Drug Approvals November 2020 FDA AcariaHealth (AH) Drug Name Manufacturer(s) Indication(s) Approval Comments Cost (WAC) Access Status Date MUSCULOSKELETAL CONDITIONS • Approved for the treatment of SMA Types 1, 2, and 3. Evrysdi • PTC Therapeutics • Spinal muscular $100,000 - risdiplam 8/7/20 Limited access • Is the first daily oral therapy approved for SMA. • Roche atrophy (SMA) $340,000/year oral solution • Will compete with Spinraza and Zolgensma. • Projected impact: incremental cost increase. • Exon 53 skipping agent. • Antisense oligonucleotide. Viltepso • Duchenne • For the treatment of DMD amenable to exon viltolarsen • NS Pharma muscular 8/12/20 Pending launch 53-skipping. $733,000/year intravenous infusion dystrophy (DMD) • Will compete with Vyondys 53. • Projected impact: cost replacement of existing therapy. NEUROLOGY • For the treatment of adults with relapsing forms of MS. • Will compete with multiple other approved Year 1: $103,000 Kesimpta agents for clinically isolated syndrome and • Multiple sclerosis ofatumumab • Novartis 8/20/20 AH has access relapsing remitting disease. Year 2 and (MS) intravenous infusion • Will compete with Ocrevus and Mayzent for beyond: secondary progressive disease. $83,000/year • Projected impact: cost replacement of existing therapies. © 2020 Envolve. All rights reserved. Continued Page 3 Pipeline Report Recent Specialty Drug Approvals November 2020 FDA AcariaHealth (AH) Drug Name Manufacturer(s) Indication(s) Approval Comments Cost (WAC) Access Status Date ONCOLOGY • For patients who have failed at least four prior therapies including an anti-CD38 monoclonal Blenrep antibody, a proteasome inhibitor, and an belantamab immunomodulatory agent. • GlaxoSmithKline • Multiple myeloma 8/5/20 Limited access $281,000/year mafodotin-blmf • Approved with a Black Box Warning intravenous infusion re: ocular toxicity. • Projected impact: cost replacement of existing therapies. • Approved for continued treatment of adults who achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and Onureg are not able to complete intensive • Acute myeloid azacitidine • Bristol-Myers Squibb 9/1/20 AH has access curative therapy. $254,000/year leukemia (AML) oral tablets • Oral dosing allows for extended drug exposure during each treatment cycle to prolong therapeutic activity. • Projected impact: cost replacement of existing therapies. • Approved for the treatment of adults with metastatic rearranged during transfection (RET) Gavreto fusion-positive NSCLC. • Non-small cell lung pralsetinib • BluePrint Medicines 9/4/20 Limited access • Will compete with Retevmo for RET-positive $234,000/year cancer (NSCLC) oral capsules NSCLC. • Projected impact: cost replacement of existing therapy. © 2020 Envolve. All rights reserved. Continued Page 4 Pipeline Report Recent Specialty Drug Approvals
Recommended publications
  • NG198 Evidence Review E1
    1 2 Research recommendations for review question: For people with mild to 3 moderate acne vulgaris what are the most effective treatment options? 4 Research question - physical modalities 5 What is the effectiveness of physical modalities (such as light devices) in the treatment of 6 acne vulgaris or persistent acne vulgaris-related scarring? 7 Why this is important 8 Physical treatments for acne are popular with people because they have the benefit of 9 treating a local area without systemic effects. They can be used in people with co-morbidities 10 or side effects where other treatments are unsuitable. They are currently available in the 11 private sector but there is no standardisation of treatment modalities or duration. Many 12 different physical therapies have been described for acne including: 13 • Comedone extraction 14 • Phototherapy – including UVB, intense pulsed light, blue and red light 15 • Photochemical therapy (e.g. photodynamic therapy) 16 • Laser 17 • Photopneumatic therapy (e.g. intense pulsed light + vacuum) 18 • Photothermal therapy (eg gold nanoparticles +light or laser) 19 Physical treatments are also used for acne scarring. These include: 20 • Punch excision 21 • CO2 laser 22 • Dermabrasion 23 • Radiofrequency (e.g. fractional microneedling, bipolar) 24 Further research is required to determine the most effective physical treatments for acne and 25 acne scarring. This could open the way to wider availability in the NHS. 26 Table 26: Research recommendation rationale Research question What is the effectiveness of physical modalities (such as light devices) in the treatment of acne vulgaris or persistent acne vulgaris-related scarring? Why is this needed Importance to ‘patients’ or the Physical treatments for acne are popular with people because population they have the benefit of treating a local area without systemic effects.
    [Show full text]
  • June 2021 Therapeutic Research Center (TRC) Is the Leading Advisory Service on Drug Therapy and Medication Management
    June 2021 Therapeutic Research Center (TRC) is the leading advisory service on drug therapy and medication management. Every month over 400,000 prescribers, pharmacists, and pharmacy technicians rely on our unbiased, evidence-based clinical recommendations to help them improve medication use, prevent medication errors, and improve patient care and outcomes. We also have one of the most extensive CE/CME course offerings in the industry. Our accredited continuing education and continuing medical education courses are trusted and relied on by hundreds of thousands of pharmacists, technicians, and prescribers every month. Therapeutic Research Center does not receive commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. Credit is reported to CPE Monitor, AAFP, and CE Broker as appropriate. Accreditation Information: Therapeutic Research Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians. Pharmacist’s Letter / Therapeutic Research Center is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Therapeutic Research Center / Prescriber’s Letter is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number:080517. Select Therapeutic Research Center courses are also acceptable for American Academy of Family Physicians (AAFP) Prescribed credit, American Osteopathic Association (AOA) credit, and American College of Emergency Physicians (ACEP) Category I Credit. Please refer to the detailed accreditation statements available online for each course. Get started at TherapeuticResearchCenter.com. Log in to access your course list or purchase a course or subscription. For additional assistance, please call 209-472-2240 and we’ll be happy to help you.
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • January 2021 Update
    PUBLISHED JULY 08, 2021 OCTOBER/DECEMBER 2020; JANUARY 2021 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the update to the Highmark Drug Formularies and pharmaceutical management procedures for January 2021. The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in October, December, and January by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Healthcare Reform Essential Formulary C. Changes to the Highmark Core Formulary D. Changes to the Highmark National Select Formulary E. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left. Highmark Blue Cross Blue Shield Delaware is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides secure, web-based portal between providers and health insurance companies. IMPORTANT DRUG SAFETY UPDATES 03/31/2021 – Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease.
    [Show full text]
  • Acne Vulgaris
    CLINICAL REVIEW What’s New in the Management of Acne Vulgaris Leon H. Kircik, MD A better understanding of acne pathophysiology and the PRACTICE POINTS role of inflammation has, however, yielded a better under- • Sarecycline is the first new antibiotic approved for standing of how existing therapies treat the disease and acne in several years. have led to more comprehensive treatment strategies that • Tazarotene foam 0.1% was relaunched to the market. are multitargeted. Nonetheless, topical and oral antibiotics The foam formulation attempts to impart moisturizing remain mainstays of acne therapy, along with topical reti- effects to offset potential irritation. noids and benzoyl peroxide. Current guidelines of care for • Topical minocycline for acne optimizes the therapeutic acne emphasize strategies that reduce dependence on anti- effects while reducing systemic effects. biotics and minimizecopy the risk for resistance.4 The therapeutic • Clascoterone and cannabidiol currently are under landscape might at last be shifting, with new chemical enti- investigation for acne treatment. ties for acne and several novel formulations in development. Sarecycline: A Novel Tetracycline Tetracyclinenot antibiotics have been used to manage acne Drug development continues to focus on the challenge of treat- since the 1950s, but their method of action in the disease ing acne effectively and safely. Inflammation is a backdrop to has not been fully elucidated.5 In addition to antibiotic the commonly cited elements of the pathophysiology of acne: effects, tetracyclines have been shown to confer anti- Propionibacterium acnes proliferation, increased sebum Dopro- inflammatory properties and other biologic effects.6,7 duction with an increase in circulating androgens, and faulty keratinization.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • 62. Deutscher Kongress Für Endokrinologie
    62. Deutscher Kongress für Endokrinologie dge2019.de TAGUNGS- FÜHRER 20.–22. März 2019 © Conny Blaack M.A., kunst & mediendesign, 37130 Gleichen/Bremke GÖTTINGEN Kongresspräsidentin: HAUPTTHEMEN Prof. Dr. Heide Siggelkow Knochen als hormonelles Organ Wissenschaftliche Kongresssekretärin: Vitamin D, das endokrine und Dr. Katja Gollisch metabolische System Kongressorganisation: Individualisierte Osteoporosetherapie EndoScience Endokrinologie Service GmbH Update Andrologie nach Berthold Endokrine Onkologie Mittwoch, 20.03.2019 Programmübersicht Raum Lichtenberg Raum Gauss Raum Heisenberg Raum Gebrüder Grimm Raum Göttinger Sieben 09:00 – 10:30 Vorstandssitzung 09:00 – 12:00 S. 18 Sektionstreffen YARE / MuSkITYRS 10:30 – 11:30 Pressekonferenz S. 18 S. 18 11:30 – 12:30 Eröffung der Industrieausstellung S. 19 12:30 – 13:00 Kongresseröffnung S. 19 13:00 – 13:45 Aktuelles zur Mikrobiom-Hor- mon-Achse: Prof. Dr. Bar- bara Obermayer- Pietsch, Graz, Österreich S. 19 13:45 – 14:15 Lunch 13:45 – 14:45 Akromegalieregister 14:00 – 15:00 Neugründung 14:15 – 15:15 14:00 – 16:00 S. 19 der AG Labor Satelliten Symposium 1: 14:15 – 15:45 S1: Vom Tiermodell zum UCB Pharma GmbH S. 20 Satelliten Symposium 2: Menschen – Aktuelles S. 22 Merck Serono GmbH zur Reproduktions- endokrinologie S. 22 15:45 – 16:15 Kaffeepause S. 20 16:00 – 17:30 16:15 – 17:15 16:00 – 17:30 S2: Hypophysen- Sektionstreffen MTE 1 16:15 – 17:45 15:00 – 19:15 erkrankungen Reproduktions- MTE 2 S3 Hauptthema: Endokrinologie in der Schwangerschaft biologie und -medizin Cortisol und Knochen: für die Praxis S. 24 Freunde oder Feinde? update 2019 S. 23 S. 23/24 (kostenpflichtig) separate Anmeldung S.
    [Show full text]
  • NG198 Evidence Review F1
    FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Research recommendations for review question: For people with moderate to severe acne vulgaris what are the most effective treatment options? Research question - reduced dose oral isotretinoin What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why this is important Oral isotretinoin is prescribed by consultant dermatologist-led team for severe forms of acne resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy. The daily dose typically ranges between 0.5mg to 1mg/kg, however dosage adjustments may be required for people with severe intolerances or whom are at higher risk of developing serious adverse effects. There is limited high-quality data on the efficacy and optimum treatment duration of reduced (less than 0.5mg/kg) daily dose isotretinoin in acne. Furthermore, there have been reports of the successful use of reduced daily dose isotretinoin, including weekly (mini) or bi-weekly (micro) dosage regime as maintenance therapy in people with recurrent relapse despite adequate response to multiple courses of isotretinoin. The evidence for reduced dose isotretinoin as maintenance therapy have been limited to case series and small cohort studies. Further research will help to establish if • reduced daily dose of oral isotretinoin is effective in the treatment of acne vulgaris • reduced dose isotretinoin regime is effective as maintenance therapy; and • the optimum duration of treatment. Table 26: Research recommendation rationale Research question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why is this needed Importance to ‘patients’ or the The daily dose of isotretinoin prescribed usually ranges between population 0.5mg – 1mg/kg.
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213433Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRISK) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type NDA Application Number 213433 PDUFA Goal Date August 27, 2020 OSE RCM # 2019-1748 Reviewer Name Yasmeen Abou-Sayed, PharmD Acting Team Leader Jacqueline Sheppard, PharmD Acting Deputy Division Doris Auth, PharmD Director Review Completion Date August 21, 2020 Subject Evaluation of Need for a REMS Established Name clascoterone Trade Name Winlevi Name of Applicant Cassiopea SpA Therapeutic Class Androgen receptor inhibitor Formulation 1% Topical cream Dosing Regimen Applied to the affected areas twice daily 1 Reference ID: 4660260 Table of Contents EXECUTIVE SUMMARY ......................................................................................................................................................... 3 1 Introduction ..................................................................................................................................................................... 3 2 Background ...................................................................................................................................................................... 3 2.1 Product Information ..........................................................................................................................................
    [Show full text]
  • 213433Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213433Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multidisciplinary Review and Evaluation: NDA 213433 WINLEVI (clascoterone) cream, 1% NDA Multidisciplinary Review and Evaluation Application Type NME- In “The Program” Application Number(s) NDA 213433 Priority or Standard Standard Submit Date(s) August 19, 2019 Received Date(s) August 27, 2019 PDUFA Goal Date August 27, 2020 Division/Office Shari Targum, Deputy Director, Division of Dermatology and Dentistry Julie Beitz, Director Office of Immunology and Inflammation Review Completion Date Established/Proper Name Clascoterone cream, 1% (Proposed) Trade Name WINLEVI Pharmacologic Class NME Code Name N/A Applicant Cassiopea SpA Dosage Form Topical cream Applicant proposed Dosing Apply a thin layer (approximately 1 gram) to affected area Regimen twice daily (morning and evening) Applicant Proposed For the treatment of acne vulgaris in patients 9 years of age Indication(s)/Population(s) and older Applicant Proposed SNOMED CT Indication Disease Term for Each Proposed Indication Recommendation on Regulatory Action Approval Recommended For the treatment of acne vulgaris in patients 12 years of age Indication(s)/Population(s) and older (if applicable) Recommended SNOMED CT Indication Disease Term for Each Indication (if applicable) Recommended Dosing Apply a thin layer (approximately 1 gram) to affected area Regimen twice daily (morning and
    [Show full text]
  • Health Plan Insights
    Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
    [Show full text]
  • Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary
    Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary Effective September 1, 2021 Health Plan Products: Kaiser Permanente Bernard J. Tyson School of Medicine, EPO Student Blanket Health Plan offered by Kaiser Permanente Insurance Company For the most current list of covered medications or for help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit: Call 1-800-533-1833, TTY 711, Monday through Friday, 7 a.m. to 9 p.m. ET Visit kaiserpermanente.org to: • Find a participating retail pharmacy by ZIP code. • Look up possible lower-cost medication alternatives. • Compare medication pricing and options. • Find an electronic copy of the formulary here. • Get plan coverage information. For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit kp.org/kpic-websiteTBD The formulary is subject to change and all previous versions of the formulary are no longer in effect. Kaiser Permanente Last updated: September 1, 2021 Table of Contents Informational Section...........................................................................................................................................3 ANTIHISTAMINE DRUGS - Drugs for Allergy.....................................................................................................9 ANTI-INFECTIVE AGENTS - Drugs for Infections...........................................................................................
    [Show full text]